Linde Healthcare has developed a complete solution, INOmax® Therapy, for the delivery of inhaled nitric oxide. Our solution integrates a dedicated delivery system and support for the most effective treatment results and patient safety.
In conjunction with ventilatory support and other appropriate agents, INOmax is indicated for the treatment of newborns ≥ 34 weeks gestation with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, in order to improve oxygenation and to reduce the need for extracorporeal membrane oxygenation.
The safety and efficacy of nitric oxide is critically dependent on the administration device. The INOvent® delivery device fits every sort of ventilatory support mode and enables constant monitoring of delivered nitric oxide, oxygen and nitrogen dioxide. Our solution includes service and technical assistance as well as staff training.